Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from UK research institutions.

Collection of images illustrating the breadth of translational research taking place at University of Oxford

The award follows Oxford’s recent top ranking in the UK for generating spin-out companies and its success in the Research Excellence Framework (the national research assessment exercise), which showed Oxford’s submission had the highest volume of world-leading research. 

Today’s news means the University has been awarded the largest amount of IAA funding in the UK, to jumpstart knowledge exchange, translation and commercialisation of research across all disciplines.

The programme, now in its tenth year, has provided crucial early-stage support to Oxford start-ups that are now established global businesses.

Improved diagnosis of blood diseases

SEREN is a Social Enterprise Based at the Muhimbili University for Health and Allied Sciences (MUHAS) in Dar-es-Salaam, Tanzania that is delivering DNA-based diagnostics improving outcomes of children and young adults with blood diseases in sub-Saharan Africa. 

Thanks to IAA funding, the team in close collaboration with the Muhimbili National Hospital and the patient charity Tumaina la Maisha, have put in place the required infrastructure to facilitate national patient referrals, local sequencing, joint cloud-based data analysis and clinical data collection for the WHO Cancer Registry. Together with their African collaborators, they have put in place frameworks to consent parents/patients for DNA analysis and to provide diagnostic-grade DNA testing for as low as $10/test. 

Read more about SEREN

Treatments for patients with blood cancer

A spin-out from the University of Oxford, the company is based on world-leading discoveries in clinical haematology and single-cell multi-omics.

IAA funding has enabled the company's founding professors to further development of targeted and curative therapies for MPNs - a group of chronic blood cancers that begin with mutations occurring in cancer stem cells in the bone marrow. 

Alethiomics’ founders have pioneered the use of single-cell multi-omic approaches to better understand the biology of mutant-positive stem cells in MPNs and to discover novel molecular targets as the basis for drug discovery. They have also developed bespoke platforms for target validation to accelerate successful translation to the clinic.

Read more about Alethiomics

 

Read the full story on the University of Oxford website

Discover how our Translational Research Office supports Oxford researchers

Similar stories

Sensory Supermarket event helps businesses make public-facing spaces more inclusive for autistic people

Researchers from the Universities of Oxford and Reading – in collaboration with awareness-raising organisation Sensory Spectacle – are hosting an innovative event called Sensory Supermarket as part of the Sensory Street research project.

Tackling suicide risk in people with mental disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients at risk of suicide.

Environmental impact of 57,000 multi-ingredient processed foods revealed

A study estimating the environmental impact of 57,000 food products in the UK and Ireland has been published by an Oxford-led research team in the journal PNAS.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

DPAG hosts successful first Science in the Park event

More than 100 children, along with around 50 parents, grandparents and caregivers enjoyed an exciting variety of activities on the theme of ‘How the Body Works’ in University Parks on Tuesday 26 July. This ‘Science in the Park’ event was run by the Department of Physiology, Anatomy & Genetics (DPAG) Outreach and Public Engagement Working Group (OPEWG) and volunteers comprising research scientists, clinical anatomy teaching staff, and graduate and undergraduate students.